Description
Lung cancer, statistics, mutations: Kras/Braf/EGFR, LKB1, p53 etc. in non-small cell lung cancer (NSCLC), treatment strategies and current ongoing clinical trials and setbacks.
mTOR/MEK/ERK signaling pathway, and autophagy signaling pathway and their upregulation in cancer, specifically lung and pancreatic cancer.
Role of autophagy in Kras driven NSCLC and recent studies for using autophagy inhibitors as potential therapy for cancer, specifically Kras driven cancers (specifically in NSCLC with Kras and LKB1 or p53 mutations)
Role of autophagy in recycling nutrients and substrates to support cancer cell survival and growth
Use of autophagy inhibitors for cancer treatment, specifically hydroxychloroquine, Lyso5, ULK1 inhibitors.
What is ferroptosis and its effect in cancer? Use of ferroptosis inhibitors (like ferrostatin-1) for cancer treatment.
Effect of autophagy on ROS generation in Kras driven NSCLC, and inducing or inhibiting ferroptosis.
Use of MEK/ERK or other MAPK signaling pathway inhibitors for the treatment of cancer, specifically Kras driven cancers and their side effects/toxicities as well as resistance to therapy, specifically upregulation of autophagy as a resistance mechanism on prolonged treatment of using these inhibitors. Use invivo/invitro and clinical studies citing Trametinib, Dabrafenib, selumetinib etc.
Effect of MEK/ERK inhibition on ROS generation in Kras driven NSCLC, and inducing or inhibiting ferroptosis.
Last Completed Projects
| topic title | academic level | Writer | delivered |
|---|
